VBIO · Valion Bio Inc. Common Stock
View on chartInsiders & Stakes
| Jennifer Ernst Chief Executive Officer | ▼ Sell | Tax Withholding | 32,691 Shares held | 12/18/2025 | View profile |
| Christina Rizopoulos Valauri Director | ▲ Buy | Open Market | 19,000 Shares held | 4/1/2026 | View profile |
| Michael K. Handley Chief Operating Officer | ▲ Buy | Option Exercise | 11,030 Shares held | 5/18/2026 | View profile |
| Sheryle Bolton Director | ▲ Buy | Open Market | 10,000 Shares held | 4/15/2026 | View profile |
| Kimberly Ann Bambach Interim CFO | ▲ Buy | Grant | 7,500 Shares held | 3/12/2024 | View profile |
| Lisa G. Wolf COO & CFO | ▼ Sell | Tax Withholding | 27 Shares held | 9/18/2026 | View profile |
Transaction History
| Lisa G. Wolf | ▲ Buy | Option Exercise | 4 | — | 9/18/2026 |
| Lisa G. Wolf | ▼ Sell | Tax Withholding | 2 | $4 | 9/18/2026 |
| Lisa G. Wolf | ▲ Buy | Option Exercise | 92 | — | 6/18/2026 |
| Michael K. Handley | ▲ Buy | Option Exercise | 2,206 | — | 5/18/2026 |
| Sheryle Bolton | ▲ Buy | Open Market | 10,000 | $10K | 4/15/2026 |
| Christina Rizopoulos Valauri | ▲ Buy | Open Market | 19,000 | $18K | 4/1/2026 |
| Lisa G. Wolf | ▲ Buy | Option Exercise | 92 | — | 3/18/2026 |
| Michael K. Handley | ▲ Buy | Option Exercise | 8,824 | — | 2/18/2026 |
| Lisa G. Wolf | ▲ Buy | Option Exercise | 736 | — | 12/18/2025 |
| Lisa G. Wolf | ▼ Sell | Tax Withholding | 302 | $565 | 12/18/2025 |
| Jennifer Ernst | ▲ Buy | Option Exercise | 14,706 | — | 12/18/2025 |
| Jennifer Ernst | ▼ Sell | Tax Withholding | 5,262 | $10K | 12/18/2025 |
| Jennifer Ernst | ▲ Buy | Grant | 22,541 | $0 | 9/22/2025 |
| Kimberly Ann Bambach | ▲ Buy | Grant | 7,500 | $0 | 3/12/2024 |
| Jennifer Ernst | ▼ Sell | Other | 26,986 | $0 | 11/12/2021 |
| Jennifer Ernst | ▼ Sell | Other | 1,391 | $0 | 11/12/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Valion Bio Completes Oral Mucosal Entolimod Formulation
Valion Bio has successfully formulated an oral mucosal version of entolimod in partnership with Shear Kershman Laboratories. The company states this development could open a needle-free pathway and significantly expand its long-term opportunity. This news contributed to the stock appearing in pre-market movers, though the shares remain well below their 52-week high of $32.50.
Valion Bio Completes Oral Mucosal Entolimod Formulation. Valion Bio has successfully formulated an oral mucosal version of entolimod in partnership with Shear Kershman Laboratories. The company states this development could open a needle-free pathway and significantly expand its long-term opportunity. This news contributed to the stock appearing in pre-market movers, though the shares remain well below their 52-week high of $32.50.